Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OncimmuneSQI DiagnosticsSernovaGeneNewsLexagene
Price Information
Current PriceGBX 110.50C$0.19C$0.20N/AC$0.86
52 Week RangeN/AN/AN/AN/AN/A
Beat the Market™ Rank
Overall Score1.
Analysis Score2.
Community Score2.
Dividend Score0.
Ownership Score3.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetGBX 150N/AN/AN/AN/A
% Upside from Price Target35.75% upsideN/AN/AN/AN/A
Trade Information
Market Cap£69.18 millionC$52.59 millionC$31.35 millionC$24.65 millionC$71.12 million
Average Volume33,554368,385321,6301,480,179238,530
Sales & Book Value
Annual Revenue£358,000.00C$1.81 millionN/AC$234,592.00N/A
Price / Sales196.0029.12N/AN/AN/A
CashflowGBX 14.13 per shareC$0.01 per shareC$0.02 per shareN/AC$0.04 per share
Price / Cash7.8231.6712.67145.0023.94
Book ValueGBX 3.60 per shareC$0.00 per shareC$0.02 per shareC($0.06) per shareC$0.04 per share
Price / Book0.31-190.00N/AN/AN/A
Net IncomeN/AN/AN/AN/AN/A
EPSGBX (16)C($0.04)C($0.03)C($0.07)C($0.11)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt-to-Equity Ratio375.32%211.45%1.74%N/A51.35%
Current Ratio3.91%0.54%8.28%0.10%14.22%
Quick Ratio3.84%0.36%7.04%0.05%12.82%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Shares Outstanding63.50 million276.79 million195.95 millionN/A85.69 million
Next Earnings DateN/A8/26/2020 (Estimated)6/26/2020 (Estimated)N/AN/A
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.